An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

Sweden: Laroprovstat, the first oral small-molecule PCSK9 inhibitor under clinical development, demonstrated substantial LDL cholesterol–lowering effects in a phase 1 study involving treatment-naive ...

Lipoprotein (a) is a cholesterol that carries lipoprotein – particles made of fats and proteins – in your blood. It’s structurally similar to LDL (low-density lipoprotein, or “bad” cholesterol), but ...

Heart specialists now recommend that everyone get tested for lipoprotein(a). Here’s what to know about it. The American Heart Association and other cardiac groups now recommend that everyone should be ...

Share on Pinterest A new study suggests elevated lipoprotein(a) levels are linked to residual cardiovascular risk. Image credit: Evgeniia Siiankovskaia/Stocksy A new study suggests that high ...

Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic ...

Elevated lipoprotein(a) [Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD), with levels >50 mg/dL affecting 20–30% of the global ...

New guidelines for managing cholesterol call for more aggressive prevention and earlier treatment, including a recommendation that all adults be tested once for lipoprotein(a), a genetic risk marker ...

WEST LAFAYETTE, Ind. — Purdue University drug discovery scholar and faculty member, entrepreneur, and philanthropist Philip Low, whose life’s work turned laboratory discoveries into therapies that ...

“Bad,” or LDL, cholesterol is a major risk factor for heart disease and most people are screened for it as part of their yearly physicals. Subscribe to read this story ad-free Get unlimited access to ...

Lipoprotein(a) is a genetic cardiovascular risk factor affecting 20% of the global population, with no routine testing despite guideline recommendations. Current therapies offer modest Lp(a) reduction ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) [Lp(a)] levels and cardiovascular disease (CVD) in women and raises questions about whether broader ...